Literature DB >> 10666681

Oxidative stress and neural dysfunction in Down syndrome.

R C Iannello1, P J Crack, J B de Haan, I Kola.   

Abstract

Total or partial trisomy of chromosome 21 occurs with relatively high frequency and is responsible for the occurrence of Down syndrome. Phenotypically, individuals with Down syndrome display characteristic morphological features and a variety of clinical disorders. One of the challenges for researchers in this field has been to ascertain and understand the relationship between the Down syndrome phenotype with the gene dosage effect resulting from trisomy of chromosome 21. Much attention therefore, has been given towards investigating the consequences of overexpressing chromosome 21-linked genes. In particular, an extensive analysis of SOD1 and APP have provided important insights as to how perturbations in the expression of their respective genes may contribute to the Down syndrome phenotype. In this review we will highlight studies which support a key role for SOD1 and APP in the pathogenesis of neural abnormalities observed in individuals with Down syndrome. Central to this relationship is how the redox state of the cell is affected and its consequences to neural function and integrity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10666681     DOI: 10.1007/978-3-7091-6380-1_17

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  23 in total

1.  Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1/BVR-a system: insights for transition to Alzheimer's disease.

Authors:  Fabio Di Domenico; Gilda Pupo; Cesare Mancuso; Eugenio Barone; Francesca Paolini; Andrea Arena; Carla Blarzino; Frederick A Schmitt; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

2.  Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome.

Authors:  Giovanna Cenini; Amy L S Dowling; Tina L Beckett; Eugenio Barone; Cesare Mancuso; Michael Paul Murphy; Harry Levine; Ira T Lott; Frederick A Schmitt; D Allan Butterfield; Elizabeth Head
Journal:  Biochim Biophys Acta       Date:  2011-10-08

Review 3.  Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism.

Authors:  Eugenio Barone; Andrea Arena; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2017-07-10       Impact factor: 7.376

Review 4.  Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications.

Authors:  D Allan Butterfield; Marzia Perluigi; Tanea Reed; Tasneem Muharib; Christopher P Hughes; Renã A S Robinson; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2012-01-18       Impact factor: 8.401

Review 5.  4-Hydroxy-2-nonenal, a reactive product of lipid peroxidation, and neurodegenerative diseases: a toxic combination illuminated by redox proteomics studies.

Authors:  Marzia Perluigi; Raffaella Coccia; D Allan Butterfield
Journal:  Antioxid Redox Signal       Date:  2012-02-15       Impact factor: 8.401

6.  Homocysteine metabolism in children with Down syndrome: in vitro modulation.

Authors:  M Pogribna; S Melnyk; I Pogribny; A Chango; P Yi; S J James
Journal:  Am J Hum Genet       Date:  2001-06-05       Impact factor: 11.025

7.  Abnormal microRNA expression in Ts65Dn hippocampus and whole blood: contributions to Down syndrome phenotypes.

Authors:  Jennifer Keck-Wherley; Deepak Grover; Sharmistha Bhattacharyya; Xiufen Xu; Derek Holman; Eric D Lombardini; Ranjana Verma; Roopa Biswas; Zygmunt Galdzicki
Journal:  Dev Neurosci       Date:  2011-10-27       Impact factor: 2.984

Review 8.  Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics.

Authors:  Marzia Perluigi; Fabio Di Domenico; D Allan Buttterfield
Journal:  Proteomics Clin Appl       Date:  2014-02       Impact factor: 3.494

Review 9.  HNE-modified proteins in Down syndrome: Involvement in development of Alzheimer disease neuropathology.

Authors:  Eugenio Barone; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2016-11-10       Impact factor: 7.376

10.  Apigenin as a Candidate Prenatal Treatment for Trisomy 21: Effects in Human Amniocytes and the Ts1Cje Mouse Model.

Authors:  Faycal Guedj; Ashley E Siegel; Jeroen L A Pennings; Fatimah Alsebaa; Lauren J Massingham; Umadevi Tantravahi; Diana W Bianchi
Journal:  Am J Hum Genet       Date:  2020-10-23       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.